Würzburg 2018 – scientific programme
Parts | Days | Selection | Search | Updates | Downloads | Help
ST: Fachverband Strahlen- und Medizinphysik
ST 5: Biomedical Imaging II
ST 5.7: Talk
Wednesday, March 21, 2018, 18:15–18:30, Phys-HS P
HYPMED - Digital Hybrid Breast PET/MRI for Enhanced Diagnosis of Breast Cancer — Florian Müller1, Federica Demattè1, Thomas Dey1, Pierre Gebhardt1, Nicolas Groß-Weege1, Patrick Hallen1, •David Schug1, Björn Weißler1, Laiyin Yin1, and Volkmar Schulz1,2 — 1Department of Physics of Molecular Imaging Systems, Institute for Experimental Molecular Imaging, RWTH Aachen University, Aachen, Germany — 2Department of Molecular Imaging Systems, Philips Research, Aachen, Germany
The combination of Positron Emission Tomography (PET) with Magnetic Resonance Imaging (MRI) is a powerful research tool for cancer diagnosis and individualized cancer treatment (precision oncology). PET-MRI can provide unique information to guide precision oncology that includes measuring the regional expression of therapeutic targets, measuring drug pharmacokinetics, measuring therapy pharmacodynamics, and providing a marker of therapeutic efficacy that is highly indicative of outcome.
Current commercial PET-MRI systems are implemented as whole body imaging devices, although MRI is mostly used as an organ-based modality. The high complexity and cost of this young hybrid imaging modality, the tracer dose and the low image resolution are limiting future investigations in the fields of genomics, proteomics or metabolomics. The EU H2020 project HYPMED is addressing these limitations by developing a dedicated PET-RF insert to improve the diagnosis of breast cancer and personalized therapy control.